Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 10, 2024 10:11 ET | Source: Research and Markets

Ovarian Cancer Pipeline Drugs Analysis, 2024: Insights on 180+ Companies and 200+ Pipeline Drugs, Including Atezolizumab (Genentech), Tisotuma Vedotin (Genmab), and SON-1010 (Sonnet Biotherapeutics)

Dublin, June 10, 2024 (GLOBE NEWSWIRE) -- The "Ovarian Cancer - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.This report provides comprehensive...
May 03, 2024 05:43 ET | Source: Research and Markets

Comprehensive Report Forecasts RUBRACA's Impact on Ovarian Cancer Treatment Market through 2032

Dublin, May 03, 2024 (GLOBE NEWSWIRE) -- The "RUBRACA Market Size, Forecast, and Drug Insight - 2032" report has been added to ResearchAndMarkets.com's offering. The global ovarian cancer...
April 13, 2020 09:00 ET | Source: ProLynx LLC

ProLynx announces Phase 1B clinical trial of its DNA-damaging agent PLX038 (PEG~SN-38) with the PARP inhibitor Rubraca® (rucaparib) at the National Cancer Institute

SAN FRANCISCO, April 13, 2020 (GLOBE NEWSWIRE) -- ProLynx LLC today announced that the first patient was treated with its PLX038 in a Phase 1B clinical trial for small-cell lung cancer at the...